Loading...

PROF PROFOUND MEDICAL CORP Product Launches 8-K Filing

PRFN

PRF

PROFOUND MEDICAL CORP

(PROF)

2026 8-K

Shareholder Meeting Results

Event Announcement

Financial Results Update

Upcoming Earnings Call

Investor Conference Update

Conference Announcement

100th Procedure Achieved

Trial Success Announcement

Investor Call Announcement

Financial Results Update

Upcoming Earnings Call

Award Announcement

Milestone Achievement

Investor Events Announcement

First Patient Treated

TULSA-PRO Update

New Treatment Milestone

Equity Offering Closed

Fundraising Announcement

Product Launch Announcement

Distribution Agreement

Distribution Rights Regained

Financial Update

Financial Results Announced

Investor Meetings

Financial Statements

Market Expansion

Investor Meetings

Shareholder Meeting

Correction Filing

Filing Amendment

Financial Restatement

Credit Agreement Update

Revenue Announcement

Filing Overview

Filing Announcement

Recent Filing Details

SEC Filing Report

Regulatory Filing

Filing Overview

Form 6-K Filing

Foreign Issuer Report

Filing Overview

6-K Filing Summary

Filing Overview

Filing Reported

Form 6-K Filing

Annual Meeting Notice

Latest Filing Update

May Filing Summary

6-K Filing Summary

Filing Announcement

Corporate Filing Summary

Filing Overview

Filing Report Summary

Filing Overview

External Links:

On January 6, 2026, Profound Medical Corp. announced that The Johns Hopkins Hospital successfully treated its first non-clinical-trial prostate cancer patient using the TULSA-PRO® system. This marks a significant step in the company's product usage beyond clinical trials.

AI Assistant

PROFOUND MEDICAL CORP

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.